Poket News

Pfizer ends COVID-19 vaccine trial to seek emergency-use authorisation


  • Pfizer Inc said on 18 Nov that final results from the late-stage trial of its COVID-19 vaccine show it was 95% effective, adding it had the required 2-months of safety data and would apply for emergency U.S. authorization within days.
  • The drugmaker said efficacy of the vaccine developed with German partner BioNTech SE was consistent across age and ethnicity demographics, and that there were no major side effects, a sign that the immunization could be employed broadly around the world